Quarterly report · Q3
9273.TEDINET S100TEGN
Period2023-07-01 → 2024-03-31
Filed2024-05-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥16.8bn | 2023-07-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥22.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥16.2bn | 2022-07-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | ¥3.6bn | 2023-07-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥3.3bn | 2022-07-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥3.6bn | 2023-07-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.1bn | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.2bn | 2022-07-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.6bn | 2023-07-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.2bn | 2022-07-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.3bn | 2023-07-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.1bn | 2022-07-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.3bn | 2023-07-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2022-07-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥30.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥28.5bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.3bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥7.5bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥22.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥20.9bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥20.3bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.8bn | at 2023-06-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥57.1 | 2023-07-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.64 | 2024-01-01 → 2024-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.83 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥52.48 | 2022-07-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.29 | 2023-01-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 75.7% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.5% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2024-03-31 | −¥1.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2024-03-31 | −¥1.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2024-03-31 | −¥11m |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥11.5bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥10.3bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2023-07-01 → 2024-03-31 | ¥1.3bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2023-07-01 → 2024-03-31 | ¥2.1bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥6.5bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥6.5bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2023-07-01 → 2024-03-31 | ¥1.5bn |
| —segment total | revenue | 2023-07-01 → 2024-03-31 | ¥18.0bn |
| —segment total | revenue external | 2023-07-01 → 2024-03-31 | ¥16.8bn |
| —segment total | revenue intersegment | 2023-07-01 → 2024-03-31 | ¥1.3bn |
| —segment total | segment profit | 2023-07-01 → 2024-03-31 | ¥3.6bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2023-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2023-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2023-03-31 | ¥16m |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥11.5bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥10.2bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2022-07-01 → 2023-03-31 | ¥1.4bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥2.0bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥6.0bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥6.0bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥1.2bn |
| —segment total | revenue | 2022-07-01 → 2023-03-31 | ¥17.5bn |
| —segment total | revenue external | 2022-07-01 → 2023-03-31 | ¥16.2bn |
| —segment total | revenue intersegment | 2022-07-01 → 2023-03-31 | ¥1.4bn |
| —segment total | segment profit | 2022-07-01 → 2023-03-31 | ¥3.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 356
| Item | Context | Value | Unit |
|---|---|---|---|
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |